MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

The Los Angeles area is seeing a troubling increase in local dengue fever cases, health officials warned Wednesday. In a ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Pharmaceutical companies are making investments in research of therapies that target three different antigen-binding sites.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company accepted offers from multiple leading biotech institutional and individual investors to ...

MSD (Merck & Co) and its wholly-owned subsidiary EyeBio have announced the start of the Phase IIb/III BRUNELLO clinical trial ...

A combined 2.1 million equity shares of the company had changed hands till 02:50 PM, and there are pending buy orders for ...

Merck, EyeBio initiate phase 2b/3 trial for Restoret to treat diabetic macular edema: Rahway, New Jersey Thursday, September 5, 2024, 10:00 Hrs [IST] Merck, known as MSD outside o ...

The vaccine has been under development since 2006, with a partnership signed with the Indian Council of Medical Research ...

Two Oral Presentations Featured Updated Ivonescimab Data from Phase II Studies in CRC and TNBC in Addition to Poster ...